House Expected To Eliminate Earmarks, give NCI $2 Billion For FY94, A $40 Million Increase
In Brief: Gene Therapy For ADA Deficiency Moves forward With Stem Cell Treatment In Caif. And At NIH
ACS Initiates Cage In Approach to Study Of alternative Methods
DT Board Oks RFAs In Surgery, HIV, Breast Cancer
Patient Costs In Trials Should Be Paid In Any Reform Plan, DCT Board Write To Shalala
FDA Simplifies Reporting Of Adverse Events
Trending Stories
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”
